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Abstract
Overcoming the intractable challenge of imaging of label-free, drug encapsulated nanoparticles in tissues in vivo would
directly address associated regulatory concerns over ’nanotoxicology’. Here we demonstrate the utility of Atomic Force
Microscopy (AFM) for visualising label-free, drug encapsulated polyester particles of ,280 nm distributed within tissues
following their intravenous or peroral administration to rodents. A surprising phenomenon, in which the tissues’ mechanical
stiffness was directly measured (also by AFM) and related to the number of embedded nanoparticles, was utilised to
generate quantitative data sets for nanoparticles localisation. By coupling the normal determination of a drug’s
pharmacokinetics/pharmacodynamics with post-sacrifice measurement of nanoparticle localisation and number, we present
for the first time an experimental design in which a single in vivo study relates the PK/PD of a nanomedicine to its
toxicokinetics.
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Introduction
Nanomedicines are multiple component systems whose distri-
bution in vivo, targeted or otherwise, remains a critical area of
understanding the clinical outcomes. [1,2] Apparently small
changes in size, shape and surface properties influence their bio-
distribution.[3–6] Understanding the bio-distribution involves use
of labelled particles that rely on fluorescence, luminescence,
optical or radioactivity [7–9] or approaches that monitor the
molecular vibrations. [10] However, labelled nanoparticles cannot
be guaranteed to model the behaviour of label-free nanoparticles
encapsulating a drug. [11,12] Nor can spectral imaging techniques
describe the micromechanical environment of tissue in which
nanoparticles reside. This uncertainty hampers progress in
evaluating the therapeutic efficacy and safety of nanomedicines,
[13,14] which ideally should be obtained during the same in vivo
experiment used to determine the nanoparticles’ tissue distribution
and environment.
In order to image the label-free, drug-encapsulated nanoparti-
cles (NPs) in the tissues, and measure the local influence of a
particle on the tissue mechanical properties, we adapted ex vivo and
in vivo imaging approaches using an AFM. Ex vivo experiments
involved the isolation of rat kidney and blood followed by their
exposure to an appropriate volume of cyclosporine (CsA)
containing NPs. In vivo experiments involved the dosing of rats
with CsA-NPs either by intravenous (iv) or peroral (po) routes,
followed by tissue isolation, sectioning and imaging/measurement
of the QNM properties (such as Young’s Modulus, E/Pa). Support
for the requirement to measure the QNM of tissues during disease
progression comes from a significant body of literature: i) the
stiffness of red blood cells (RBCs) plays a major role in whole blood
viscosity that is correlated to several cardiovascular diseases; [15]
ii) the stiffness of tissues such as liver has been established as an
independent predictor of liver failure, hepatocellular carcinoma
and mortality in cirrhotic patients; [16] iii) arterial wall stiffening,
stiffness of carotid artery and aorta is believed to increase in
diabetes and can serve as predictors for cardiovascular mortality in
end-stage renal disease; [17] iv) the change in cancer/tumor cell
stiffness affects the way these cells spread [18], and very recently
AFM has been used to study the stiffness of breast cancer tissues
from patients. [19] Thus, the AFM is a multifunctional toolbox for
the study of the nano-bio-interface, facilitating a better under-
standing of the pathology and toxicology with resolution down to
0.1 nm has made an essential tool for imaging and measure the
mechanical properties. [20] By putting the AFM toolbox in the
context of drug delivery, this study presents new possibilities by
which we can better address regulatory requirements for
nanomedicines, and understand their efficiency and biophysical
interactions of particles with tissue, which will be critical in
developing effective drug carriers. Here we address the goal of
imaging of label-free drug-encapsulated nanoparticles distributed
in various tissues in vivo and their concomitant quantitative nano-
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mechanical (QNM) properties after intravenous or peroral admin-
istration using Atomic Force Microscopy (AFM).
Materials and Methods
Materials
Poly(lactide-co-glycolic) acid (PLGA) (Resomer R503H; MW
35–40 kDa) was purchased from Boehringer Ingelheim, (Ingel-
heim, Germany). Polyvinyl alcohol (PVA) (MW 30–70 kDa) and
ethyl acetate were purchased from Sigma-Aldrich (Poole, UK).
Cyclosporine (CsA) was purchased from Fluorochem Ltd.
Derbyshire, UK.
Preparation and Characterization of CsA Encapsulated
PLGA Nanoparticles
The CsA-NPs were prepared by the emulsion–diffusion–
evaporation method. PLGA (50 mg) and CsA (7.5 mg) were
dissolved in ethyl acetate (2.5 ml) under stirring at 1000 rpm over
a period of 2 h. This drug containing polymer solution was added
in drop wise manner to 5 ml of PVA solution (1% w/v). The
resulting primary emulsion (o/w) was stirred over 1 h at 1000 rpm
followed by homogenization at 15,600 rpm for 15 min to reduce
the droplet size. The emulsion was transferred to 25 ml of water
and stirred overnight to facilitate diffusion of organic solvent and
evaporation. The drug entrapment efficiency was measured by
HPLC following previously developed method in our laboratory;
[21] the particle size was measured using zeta sizer, nanoSight
(Detailed methods of characterisation and data in the Supplement Information
Figures S1 & S2).
AFM Measurements
AFM images were obtained by scanning the mica surface in air
under ambient conditions using AFM (Digital Instruments, Santa
Barbara, CA, USA; Bruker Nanoscope analysis software Version
1.40) operated using the new PeakForce QNM mode. The AFM
measurements were obtained using ScanAsyst-air probes, and the
spring constant (Nominal 0.4 N/m) and deflection sensitivity has
been calibrated, but not the tip radius (the nominal value has been
used; 2 nm). AFM images were collected from two different
samples and at random spot surface sampling (at least five areas
per sample). The quantitative mechanical data was obtained by
measuring DMT modulus/Pa using Bruker software (NanoScope
Analysis) (Supplement Information Figure S3). To obtain the Young’s
Modulus, the retract curve is fit using the Derjaguin-Muller-
Toporov model, for that reason called DMT Modulus [22].
Ex vivo Studies with Tissues
To demonstrate the proof of concept firstly we have performed
ex vivo studies. The ex vivo studies were performed using rat blood,
plasma and serum (900 ml) to which 100 ml of CsA-NPs were
added and vortexed for 1 min and 5 ml of the respective samples
were mounted on mica followed by air drying over 10–15 min for
AFM analysis as described above. Further we have also used
freshly excised kidney from rat to which 50 ml of CsA-NPs were
injected using insulin syringe (25G needle). The particle injected
kidney was stored at 220uC over 48 h and then cut into 15 mm
sections using cryotome and mounted on mica and AFM analysis
was performed as described. The kidney without CsA-NPs also
processed under same conditions served as a control. To ascertain
the role of particle concentration on the tissue stiffness, freshly cut
sections of kidney and liver were mounted on mica and 5 ml of
CsA-NPs were placed on the sections and allowed to dry for
30 min and analysed by AFM as described.
In vivo Studies in Sprague Dawley (SD) Rats
All animal experiments included in this study were part of
ongoing studies performed under UK Home Office project licence
and had received ethical clearance from the University of
Strathclyde Ethics Review Panel. SD rats weighing 200–250 g
were used in these studies. Part 1: CsA-NPs (15 mg/Kg) were
administered to male SD rats through tail vein and sacrificed
15 min post injection. Blood was withdrawn by cardiac puncture
into an EDTA coated tube and centrifuged at 3000 rpm for
10 min at 5uC for plasma and serum separation. The organs were
collected and stored at 220uC until AFM analysis. For AFM
analysis, 5 ml of blood, plasma and serum were mounted on mica,
separately, while 15 mm sections of kidney, liver and brain were
cut using a cryotome and mounted on mica and imaged as
described above. Part 2: CsA-NPs (15 mg/Kg) were administered
to male SD rats by po route using a gavage needle. The blood was
withdrawn at 2, 4 and 6 h via the tail vein and tissues harvested
and processed as above.
Statistical Analysis
The stiffness data were analysed using Student unpaired t test
(Graph pad software). A value of p,0.05 was considered
statistically significant and p.0.05 considered insignificant.
Results, Discussion and Conclusions
CsA Particle Characteristics
The particle sizes were 280615 nm (by zeta sizer) and
254672 nm (nanoSight) (Supplement Information Figures S1&
S2). The AFM imaging of the particles revealed spherical shape
particles with average size was ,280 nm with few larger particles
of,665 nm (Figure 1 a) and had a stiffness of 962 GPa (Figure 2).
Figure 1. Ex vivo samples demonstrating proof of concept that
AFM is able to visualise label-free drug-encapsulated NPs in
tissues (a) CsA-NPs, (b) blood, (c) blood+NPs, (d) plasma, (e)
plasma+NPs, (f) serum (g), serum+NPs, (h) kidney and (i)
kidney+NPs. (representative nanoparticles are marked by yellow
arrows).
doi:10.1371/journal.pone.0064490.g001
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The drug entrapment efficiency was ,60% at 15% CsA w/w of
polymer (50 mg).
Ex vivo Studies
RBCs were stacked and donut shaped with a stiffness of
1.660.4 GPa (Figure 1b and Figure 2). On spiking the CsA-NPs
(100 ml) to the blood (963 GPa), plasma (662 GPa) or serum
(261 GPa), the particles were clearly visible in all three
components and their stiffness also increased significantly
(Figure 1c–g and Figure 2). It should be noted that we did not
expect the stiffness of the control NPs and untreated blood/
plasma/serum to sum to the stiffness of blood/plasma/serum
spiked with NPs. This is on account of the variance in the precise
particle number, and which cannot be equally exactly controlled
since dosing of NPs must be by volume of suspended particles. The
consequence of an increase in the stiffness of NPs and the treated
RBCs may be damaging levels of shear stress on endothelial layer,
which could be considered analogous to sickle cell anaemia. [23]
With regard to kidney sections, the control (untreated) tissue
(Figure 1h) was much softer compared to the tissue treated with
the CsA-NPs, and the individual CsA-NPs were clearly imaged
(Figure 1i, Figure 2). To further establish the role of the NPs in
modulating tissue stiffness, a drop (5 ml) of CsA-NPs was added to
15 mm thick sections of kidney (2.660.3 GPa) and liver
(762 GPa), resulting in a significant increase in tissue stiffness
(2465 GPa & 50615 GPa respectively) (Figure 3 a & b)
compared to particle treated tissue which was sectioned later
and imaged (Figure 1i). This clearly establishes the role of particle
distribution in the tissues and their concentration in altering tissue
stiffness. The ex vivo studies established the experimental platform
for the subsequent in vivo experiments where the challenge was to
Figure 2. Quantitative nano-mechanical properties of nanoparticles only and various ex vivo/in vivo tissues untreated or treated.
Tissue stiffness is measured as Young’s Modulus (GPa) *p,0.05; **p,0.01; ***p,0.001 a vs control, ex vivo & oral (not applicable to serum, liver &
kidney).
doi:10.1371/journal.pone.0064490.g002
Figure 3. Tissue sections (15 mm) of (a) kidney and (b) liver
spotted with 5 ml of CsA-NPs. The numbers in parenthesis
represents tissue stiffness (representative nanoparticles are marked by
yellow arrows).
doi:10.1371/journal.pone.0064490.g003
Figure 4. Tissue sections (a) blood, (b) plasma, (c) serum and
(d) liver of rats which were dosed iv with 15 mg/Kg CsA-NPs
and sacrificed 15 min post-dosing (representative nanoparti-
cles are marked by yellow arrows).
doi:10.1371/journal.pone.0064490.g004
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track the CsA-NPs distribution after iv or po administration.
In vivo Studies
The AFM images revealed CsA-NPs distribution in various
tissues within 15 min after dosing and the particle presence
altering the tissue stiffness (Figure 2 & 4). Though we could not
observe the particle distribution in tissues such as kidney and brain
sections, their stiffness was much higher compared to the
respective controls that could be due to the distribution of NPs
in these tissues (Supplement Information Figure S4).
On po dosing, the CsA-NPs were tracked into the blood after
6 h post-dosing, and were also detected in plasma and serum
samples at 6 h (Figure 5 a–c). The stiffness of these samples was
much higher compared to their respective controls but lower than
for the iv group. This difference may be attributed to the amounts
of NPs absorbed after po dose. Even in the po group, NPs were
detected only in the liver (Figure 5d) but not the kidney and brain
or blood/plasma samples of 2 and 4 h (Supplement Information Figure
S5). The stiffness was also not as pronounced as it was in the iv
group for the same tissues (Figure 2). This could be due to the
limited absorption of the CsA-NPs within 6 h where a major
portion of the particles on po dosing remained in the small intestine
(Figure 5e) which is not surprising as majority of the reports on
PLGA nanoparticles containing drugs have shown maximum
blood concentrations drug profiles 24 h or beyond. [21,24] The
current study provides the first proof that label-free drug
encapsulated NPs can be tracked in various tissues, though the
pathways of uptake on po dosing remain to be investigated.
In summary, we demonstrate for the first time the presence of
label-free, drug-encapsulated NPs in the tissues and the concom-
itant change in the local mechanical properties of the tissue
(Supplement Information Figure S6). The AFM methodology proposed
here now allows us to relate the clinical outcome post-dosing of an
animal with a nanomedicine’s morphological properties of size,
shape, topology, etc. [25] Given the imaging resolution of AFM it
could further be envisaged that NP degradation in vivo could also
be related to the tissue mechanical properties. This would allow us
to discriminate between toxicity caused by drug versus particle and
drug-encapsulated particle. The ability to detect NPs in blood also
envisages a simple in vitro diagnostic tool for monitoring post-
dosing without animal sacrifice. The present study holds
importance in the context of unconventional drug delivery
technologies, such as nanoparticles, that are currently exploited
in the industry for product life cycle extension [26].
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